Olavo Feher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Olavo Feher has a total of 64 co-authors. Here are the top co-authors by number of shared publications:
- Gustavo Nader Marta
Department of Radiation Oncology, Hospital Sírio-Libanês, São Paulo, Brazil; Latin America Cooperative Oncology Group, Porto Alegre, Brazil; Department of Radiology and Oncology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
3 shared publications - Manoel Jacobsen Teixeira
Universidade de São Paulo
2 shared publications - Alberto Carlos Capel Cardoso
Neurosurgery Group, Hospital Sírio-Libanês, Brazil
1 shared publication - Aline Bobato Lara Gongora
Latin American Cooperative Oncology Group (LACOG), Porto Alegre, Brazil; Hospital Sírio-Libanês, São Paulo, Brazil
1 shared publication - Allan Andresson Lima Pereira
Department of Gastrointestinal Medical Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
1 shared publication - Ana M. Mencarini
Universidade de São Paulo
1 shared publication
Latest Publications
- Open Access
- 2 September 2021
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 4, 100066
Social determinants of health and survival on Brazilian patients with glioblastoma: a retrospective analysis of a large populational database
- 2 September 2021
- Published by Elsevier in The Lancet Regional Health - Americas
- Vol. 4, 100066
Open AccessSocial determinants of health and survival on Brazilian patients with glioblastoma: a retrospective analysis of a large populational database
- Open Access
Treatment Outcomes for Adult Patients with Localized Osteosarcoma Treated with Chemotherapy without Methotrexate
Background: Standard treatment for pediatric patients with localized osteosarcoma include high-dose methotrexate (HDMTX) and cure rates greater than 60% are observed. In adult patients, however, the toxicity profile limits the use of HDMTX and it is usually excluded from chemotherapy protocols for this group. We aimed to evaluate the outcomes of adult patients with localized osteosarcoma treated with chemotherapy without methotrexate. Methods: In this retrospective cohort, we evaluated adult patients with high-grade osteosarcoma who received treatment with chemotherapy without methotrexate in a reference cancer center from 2007 to 2018. Outcomes analyzed were recurrence-free survival (RFS), overall survival (OS), and prognostic factors associated with overall survival. Results: A total of 48 patients had localized disease and received treatment with chemotherapy without methotrexate. The majority of them received chemotherapy with a combination of cisplatin and doxorubicin (N=42, 87.5%). Median age was 27 years. (range 16.8 – 66.7) With a median follow-up of 29.2 months, median RFS was 29.9 months. Median OS was not reached. 5-year RFS and OS rates were 35.1% (95% CI 20.3 – 50.2%) and 71.6% (95% CI 52.3 – 84.2%), respectively. Patients who received cumulative doses of doxorubicin ≥ 375 mg/m2 had better OS than those who received lower doses (HR 0.26, 95% CI 0.07 – 0.94, P = 0.041). Similarly, patients who received ≥ 6 cycles of neoadjuvant/ adjuvant cisplatin tended to have better OS than those who received < 6 cycles (HR 0.30, 95% CI 0.08 – 1.09, P = 0.069).Nineteen patients received less than 6 cycles of cisplatin and doxorubicin mainly because of grade 3 or 4 toxicities (11), disease progression (6),patient refusal(1), physician choice(1). Conclusion: In our study, adult patients with localized high-grade osteosarcoma who were treated with chemotherapy without methotrexate had unfavorable outcomes. The cumulative doxorubicin dose and the number of cisplatin/doxorubicin cycles were associated with improved OS. The investigation of additional treatment strategies is of utmost importance to improve adult patients outcomes.
Open AccessTreatment Outcomes for Adult Patients with Localized Osteosarcoma Treated with Chemotherapy without Methotrexate
Background: Standard treatment for pediatric patients with localized osteosarcoma include high-dose methotrexate (HDMTX) and cure rates greater than 60% are observed. In adult patients, however, the toxicity profile limits the use of HDMTX and it is usually excluded from chemotherapy protocols for this group. We aimed to evaluate the outcomes of adult patients with localized osteosarcoma treated with chemotherapy without methotrexate. Methods: In this retrospective cohort, we evaluated adult patients with high-grade osteosarcoma who received treatment with chemotherapy without methotrexate in a reference cancer center from 2007 to 2018. Outcomes analyzed were recurrence-free survival (RFS), overall survival (OS), and prognostic factors associated with overall survival. Results: A total of 48 patients had localized disease and received treatment with chemotherapy without methotrexate. The majority of them received chemotherapy with a combination of cisplatin and doxorubicin (N=42, 87.5%). Median age was 27 years. (range 16.8 – 66.7) With a median follow-up of 29.2 months, median RFS was 29.9 months. Median OS was not reached. 5-year RFS and OS rates were 35.1% (95% CI 20.3 – 50.2%) and 71.6% (95% CI 52.3 – 84.2%), respectively. Patients who received cumulative doses of doxorubicin ≥ 375 mg/m2 had better OS than those who received lower doses (HR 0.26, 95% CI 0.07 – 0.94, P = 0.041). Similarly, patients who received ≥ 6 cycles of neoadjuvant/ adjuvant cisplatin tended to have better OS than those who received < 6 cycles (HR 0.30, 95% CI 0.08 – 1.09, P = 0.069).Nineteen patients received less than 6 cycles of cisplatin and doxorubicin mainly because of grade 3 or 4 toxicities (11), disease progression (6),patient refusal(1), physician choice(1). Conclusion: In our study, adult patients with localized high-grade osteosarcoma who were treated with chemotherapy without methotrexate had unfavorable outcomes. The cumulative doxorubicin dose and the number of cisplatin/doxorubicin cycles were associated with improved OS. The investigation of additional treatment strategies is of utmost importance to improve adult patients outcomes.
- Open Access
- 7 September 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-7
The first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report
NUT midline carcinoma is a rare and aggressive subset of squamous cell carcinoma, which is characterized by the translocation of nuclear protein in testis gene that is mostly fused with bromodomain and extraterminal family proteins. We describe here the first Brazilian case of NUT midline carcinoma with BRD4-NUT fusion detected in a next-generation sequencing panel and we present the clinical evolution of this patient. A 42-year-old Caucasian man was diagnosed with poorly differentiated squamous cell carcinoma of the left maxillary sinus, with negative in situ hybridization for Epstein–Barr encoding region and human papillomavirus genotyping. He received induction therapy, chemoradiotherapy with weekly systemic chemotherapy, and, concurrently, weekly intra-arterial chemotherapy. New imaging evaluation, 1 month after the end of the last treatment, revealed a good partial response in the primary lesion. However, positron emission tomography-computed tomography showed multiple suspicious lesions in his bones and lungs, which were histologically confirmed. He died exactly 2 months after metastatic disease was diagnosed. NUT midline carcinoma is usually very aggressive. Currently, there is no standard of care for treatment of NUT midline carcinoma. The definitive diagnosis must be by demonstration of NUTM1 rearrangement. Immunohistochemical staining of greater than 50% of tumor nuclei on formalin-fixed paraffin-embedded tissue using the monoclonal rabbit antibody to NUT (clone C52B1), has a specificity of 100%, and sensitivity of 87% for the diagnosis of NUT midline carcinoma. Our case is the first Brazilian case of NUT midline carcinoma with BRD4-NUT fusion.
- 7 September 2019
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 13 (1) , 1-7
Open AccessThe first report of molecular characterized BRD4-NUT carcinoma in Brazil: a case report
NUT midline carcinoma is a rare and aggressive subset of squamous cell carcinoma, which is characterized by the translocation of nuclear protein in testis gene that is mostly fused with bromodomain and extraterminal family proteins. We describe here the first Brazilian case of NUT midline carcinoma with BRD4-NUT fusion detected in a next-generation sequencing panel and we present the clinical evolution of this patient. A 42-year-old Caucasian man was diagnosed with poorly differentiated squamous cell carcinoma of the left maxillary sinus, with negative in situ hybridization for Epstein–Barr encoding region and human papillomavirus genotyping. He received induction therapy, chemoradiotherapy with weekly systemic chemotherapy, and, concurrently, weekly intra-arterial chemotherapy. New imaging evaluation, 1 month after the end of the last treatment, revealed a good partial response in the primary lesion. However, positron emission tomography-computed tomography showed multiple suspicious lesions in his bones and lungs, which were histologically confirmed. He died exactly 2 months after metastatic disease was diagnosed. NUT midline carcinoma is usually very aggressive. Currently, there is no standard of care for treatment of NUT midline carcinoma. The definitive diagnosis must be by demonstration of NUTM1 rearrangement. Immunohistochemical staining of greater than 50% of tumor nuclei on formalin-fixed paraffin-embedded tissue using the monoclonal rabbit antibody to NUT (clone C52B1), has a specificity of 100%, and sensitivity of 87% for the diagnosis of NUT midline carcinoma. Our case is the first Brazilian case of NUT midline carcinoma with BRD4-NUT fusion.
- 8 March 2019
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 143 (1) , 95-100
The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma
The standard treatment for newly diagnosed glioblastoma includes maximal safe surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) and maintenance TMZ. The impact of time to start radiation therapy (TRT) on overall survival (OS) in glioblastoma patients is controversial. The study aimed to evaluate the impact of TRT on OS in patients diagnosed with glioblastoma who received standard treatment.
- 8 March 2019
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 143 (1) , 95-100
The impact of the time to start radiation therapy on overall survival in newly diagnosed glioblastoma
The standard treatment for newly diagnosed glioblastoma includes maximal safe surgical resection followed by concurrent radiation therapy and temozolomide (TMZ) and maintenance TMZ. The impact of time to start radiation therapy (TRT) on overall survival (OS) in glioblastoma patients is controversial. The study aimed to evaluate the impact of TRT on OS in patients diagnosed with glioblastoma who received standard treatment.
- Open Access
- 6 September 2018
- Published by Georg Thieme Verlag KG
- Vol. 37 (S 01) , A8443
Preoperative Karnofsky Performance Scale score is the best prognostic factor in patients with multiple brain metastases
Introduction: Brain metastases represent the most critical neurological complication in cancer patients. Although numerous prognostic factors have been described for these patients, there is little consensus regarding which works best. Identifying the most efficient way to determine prognosis could help professionals make a more confident and well-informed decision regarding the choice to operate patients on a case-by-case basis. Objectives: With the aim of identifying the best prognostic factors, we assessed the correlation between 16 patient-specific criteria and survival length in a group of 85 patients with multiple brain metastases who were submitted to surgical lesion resection at our institution. Methods: A group of 85 patients harboring brain metastases and submitted to neurosurgical treatment at our institution were enrolled in this retrospective analysis. We identified subgroups with short (death < 2 months after surgery) versus longer (> 1 year) survival and assessed their correlation with the following 16 variables: age, sex, body mass index, histological type, pre-operative Karnofsky Performance Scale score, platelet number, lactate dehydrogenase level, time between cancer diagnosis and brain surgery, presence of extra-cranial disease, number of intracranial lesions, Graded Prognostic Assessment, post-operative radiation, radiological pattern, presence of a lesion in the posterior fossa, volume of the larger intracranial lesion, and presence of neurological symptoms at the time of diagnosis. Results: Preoperative KPS score was significantly associated with both short (< 2 months; p < 0.001) and longer (> 1 year; p < 0.05) survival, as was post-operative irradiation (p < 0.001 for the < 2 month group and p < 0.05 for the > 1 year group). Furthermore, the multiple logistic regression model revealed that both KPS score and symptom duration were protective factors in the < 2 months group (OR 0.93; 95% CI 0.90–0.97, and 0.19; 95% CI 0.05–0.68, respectively). Conclusions: Among the various criteria we assessed, the two factors most significantly associated with both short and longer survival rates after surgery were the patient’s preoperative functional status and the use of postoperative radiotherapy. We conclude that KPS is the best prognostic factor for patients with multiple brain metastases and should therefore be used to determine the need for surgical resection.
- 6 September 2018
- Published by Georg Thieme Verlag KG
- Vol. 37 (S 01) , A8443
Open AccessPreoperative Karnofsky Performance Scale score is the best prognostic factor in patients with multiple brain metastases
Introduction: Brain metastases represent the most critical neurological complication in cancer patients. Although numerous prognostic factors have been described for these patients, there is little consensus regarding which works best. Identifying the most efficient way to determine prognosis could help professionals make a more confident and well-informed decision regarding the choice to operate patients on a case-by-case basis. Objectives: With the aim of identifying the best prognostic factors, we assessed the correlation between 16 patient-specific criteria and survival length in a group of 85 patients with multiple brain metastases who were submitted to surgical lesion resection at our institution. Methods: A group of 85 patients harboring brain metastases and submitted to neurosurgical treatment at our institution were enrolled in this retrospective analysis. We identified subgroups with short (death < 2 months after surgery) versus longer (> 1 year) survival and assessed their correlation with the following 16 variables: age, sex, body mass index, histological type, pre-operative Karnofsky Performance Scale score, platelet number, lactate dehydrogenase level, time between cancer diagnosis and brain surgery, presence of extra-cranial disease, number of intracranial lesions, Graded Prognostic Assessment, post-operative radiation, radiological pattern, presence of a lesion in the posterior fossa, volume of the larger intracranial lesion, and presence of neurological symptoms at the time of diagnosis. Results: Preoperative KPS score was significantly associated with both short (< 2 months; p < 0.001) and longer (> 1 year; p < 0.05) survival, as was post-operative irradiation (p < 0.001 for the < 2 month group and p < 0.05 for the > 1 year group). Furthermore, the multiple logistic regression model revealed that both KPS score and symptom duration were protective factors in the < 2 months group (OR 0.93; 95% CI 0.90–0.97, and 0.19; 95% CI 0.05–0.68, respectively). Conclusions: Among the various criteria we assessed, the two factors most significantly associated with both short and longer survival rates after surgery were the patient’s preoperative functional status and the use of postoperative radiotherapy. We conclude that KPS is the best prognostic factor for patients with multiple brain metastases and should therefore be used to determine the need for surgical resection.
- 1 September 2017
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 28 (8) , 915-921
Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma
Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities. The secondary endpoints included overall survival (OS) and disease-free survival. Despite lower average age (35.0±12.1 vs. 18.9±2.1 years), group 2 presented more grade 3–4 thrombocytopenia (0 vs. 15.8%) and mucositis (0 vs. 21.1%), whereas group 1 presented more grade 3–4 neutropenia (46.6 vs. 26.3%). No grade 3–4 renal toxicities occurred. Two grade 5 toxicities occurred in group 2, both after the first HDM cycle. Disease-free survival (4.38±0.61 vs. 2.3±0.54 years, P=0.228) and OS (4.70±0.56 vs 2.52±0.57 years, P=0.107) were not statistically different, but presented a trend toward better outcomes in group 1. The 4-year OS was 65.6 and 32.8% for groups 1 and 2, respectively. HDM was associated with greater severe and lethal toxicity when added to CP and DOX in AOS. In addition, it does not seem to impact on treatment efficacy. These data do not support the use of HDM for the perioperative treatment of AOS.
- 1 September 2017
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 28 (8) , 915-921
Perioperative chemotherapy with and without high-dose methotrexate in adult osteosarcoma
Treatment of adult osteosarcoma (AOS) includes perioperative chemotherapy and surgery. Standard chemotherapy consists of cisplatin (CP) and doxorubicin (DOX). Although considered the standard of care for pediatric patients, high-dose methotrexate (HDM) remains controversial in adults. We aimed to evaluate the role of HDM in AOS treated with curative intent. This study included patients with AOS who received perioperative chemotherapy with DOX and CP (group 1; N=16) and DOX, CP, and HDM (group 2; N=10). The primary endpoint was grade 3 or superior toxicities. The secondary endpoints included overall survival (OS) and disease-free survival. Despite lower average age (35.0±12.1 vs. 18.9±2.1 years), group 2 presented more grade 3–4 thrombocytopenia (0 vs. 15.8%) and mucositis (0 vs. 21.1%), whereas group 1 presented more grade 3–4 neutropenia (46.6 vs. 26.3%). No grade 3–4 renal toxicities occurred. Two grade 5 toxicities occurred in group 2, both after the first HDM cycle. Disease-free survival (4.38±0.61 vs. 2.3±0.54 years, P=0.228) and OS (4.70±0.56 vs 2.52±0.57 years, P=0.107) were not statistically different, but presented a trend toward better outcomes in group 1. The 4-year OS was 65.6 and 32.8% for groups 1 and 2, respectively. HDM was associated with greater severe and lethal toxicity when added to CP and DOX in AOS. In addition, it does not seem to impact on treatment efficacy. These data do not support the use of HDM for the perioperative treatment of AOS.
- 1 December 2015
- Published by Elsevier in Oral Oncology
- Vol. 51 (12) , 1069-1075
Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives
- 1 December 2015
- Published by Elsevier in Oral Oncology
- Vol. 51 (12) , 1069-1075
Induction chemotherapy for oral cavity cancer patients: Current status and future perspectives
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.
- 2 August 2014
- Published by Springer Nature in Journal of Neuro-Oncology
- Vol. 120 (2) , 399-403
Antiepileptic drug prophylaxis in primary brain tumor patients: is current practice in agreement to the consensus?
The role of antiepileptic drugs (AED) prophylaxis in primary brain tumor (PBT) seizure-naïve patients remains unclear. Additionally, AED are associated with severe side effects, negative impact on cognition and drug interactions. Little is known about current practice regarding prophylactic AED use in PBT. We investigated its use in a tertiary care cancer center. We reviewed medical records of 260 patients registered in our center between 2008 and 2012, focusing on prophylactic AED use. A descriptive analysis was performed with SPSS IBM version 20.0. Median age was 44.5 years (11–83). Most patients had ECOG PS ≤1 (76.4 %). Among 141 seizure-naïve patients, 70.2 % received an AED as primary prophylaxis (PP). Most commonly used drugs as PP were phenytoin (85.9 %), carbamazepine (6.1 %) and phenobarbital (5.1 %). In only 14 patients (14.1 %) AEDs were eventually discontinued, in a median time of 5.9 months (1.1–76.8 m). AED were used as PP in 60 % of low-grade gliomas, 73.3 % of anaplastic gliomas and 93.9 % of glioblastoma patients. Twenty-seven patients (27.3 %) on PP presented seizures, generally associated with tumor progression. Of the 42 seizure-naïve patients not receiving AED prophylaxis, only two presented seizures, which occurred during or within the first week post-radiotherapy. In this cross-sectional study, prophylactic AED use in PBT was extremely high. Postoperatively, AED were discontinued in a minority of patients, mostly after a prolonged period. Current prophylactic AED use patterns in PBT are not in accordance with established guidelines.